Akèy › Sipwa › Kalifòni › Los Angeles
Etid klinik pou Sipwa nan Los Angeles, CA
15 etid pou Sipwa ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 2
- Los Angeles Institute for Metabolic Research /ID# 282059, Los Angeles
Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients
Ap rekrite
- Cedars Sinai Medical Center, Los Angeles
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Ap rekriteFaz 3
- Los Angeles Institute for Metabolic Research, Los Angeles
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Ap rekriteFaz 3
- Childrens Hospital of Los Angeles, Los Angeles
- UCLA Mattel Children's Hospital, Los Angeles
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Ap rekriteFaz 3
- Inglewood Clinical, Los Angeles
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 3
- AURORA-1 Clinical Site, Los Angeles
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Ap rekriteFaz 3
- AURORA-2 Clinical Site, Los Angeles
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
Ap rekriteFaz 3
- Los Angeles Institute for Metabolic Research, Los Angeles
Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication
Ap rekriteVolontè an sante akeyi
- UCLA Center for Human Nutrition, Los Angeles
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Ap rekriteFaz 4
- Metropolis Dermatology, Los Angeles
Avoid and Resist Strategies for Weight Management
Ap rekriteVolontè an sante akeyi
- Cedars-Sinai Medical Center, Los Angeles
BrainWeighve App Feasibility Study
Ap rekriteVolontè an sante akeyi
- UCLA Marion Davies Children's Center, Los Angeles
eMOTION: Examining Implicit Attitudes in Physical Activity Engagement
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Univeristy of Southern California, Los Angeles
Tirzepatide for Alcohol Use Disorder
Ap rekriteFaz 2
- Keck School of Medicine, University of Southern California, Los Angeles
eMOTION: Examining Affective Mechanisms in Physical Activity Engagement
Ap rekriteVolontè an sante akeyi
- University of Southern California, Los Angeles
Etid Sipwa nan lòt vil
- San Antonio, TX34 etid
- Houston, TX33 etid
- Chicago, IL28 etid
- Orlando, FL27 etid
- Las Vegas, NV23 etid
- Miami, FL23 etid
- Atlanta, GA20 etid
- Dallas, TX20 etid
- New York City, NY19 etid
- Jacksonville, FL19 etid
- Washington, DC19 etid
- Austin, TX18 etid
Lòt etid nan Los Angeles
- Kansè Poumon ki pa ti selil87 etid
- Kansè (tout kalite)73 etid
- Kansè nan tete72 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè ovè50 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.